Results 171 to 180 of about 2,438,119 (300)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Task sharing for point-of-care testing: Review of national health policies and implementation landscape in 19 African countries. [PDF]

PLOS Glob Public Health
Ndlovu Z, Assane MI, Ocen F, Lamou KC, Mandona M, Mphande-Nyasulu F, Kabwe E, Fongwen NT, Said HM, Emmanuel O, Elom E, Chipuka S, Nabadda S, Bitilinyu-Bangoh J, Lesuk G, Bowen N, Adama D, Mlisana K, George JA, Melese D, Ayana G, Ndombe R, Johnson CC, Bekelynck A, Ondoa P, Loembé MM, Ellman T, Ndlovu N, Fatti G, Otieno Odhiambo C.   +29 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Recent Advances in Aptamer-Based Point-of-Care Testing. [PDF]

Sensors (Basel)
Luo S, Zhang X, Zhang Y, Qu X, Sun Q, Peng T, Yuan Q.   +6 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Challenges in Diagnosing Post-COVID Pneumonia in Kazakhstan - The Role of Point-of-Care Testing: A Letter to the Editor. [PDF]

Iran J Med Sci
Ablakimova N, Rachina S, Smagulova G, Mussina A, Sakhanova S, Smagulova D, Kozhantayeva S, de Silva HR.   +7 more
europepmc   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

A point-of-care testing device for monkeypox virus integrating recombinase polymerase amplification and lateral flow assay. [PDF]

BMC Med
Yu J, Di B, Zhou L, Zhao Y, Zhang D, Hong W, Cao L, Liang H, Jia H, Gu B.   +9 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Assessment of cardiac biomarker "point-of-care" testing as postmortem diagnostic tool. [PDF]

Int J Legal Med
Federspiel JM, Kettner M, Potente S, Heinbuch S, Lux C, Verhoff MA, Ramsthaler F.   +6 more
europepmc   +1 more source